The pivotal trials leading to FDA approval demonstrated reductions in visceral adipose tissue of approximately 15 to 20% over 26 weeks in HIV lipodystrophy patients, with continued reduction at 52 weeks
Perceived Value of a Single-Vial Product Value perceptions may vary, with flexibility and low commitment being appealing to some, and long-term convenience to others
It forms adducts with various cellular components

Whey protein hydrolysate (from milk ), Vegetable oils (Palm oil, Rapeseed oil, Sunflower oil, High oleic sunflower oil, Coconut oil), Glucose syrup, Galacto-oligosaccharides (GOS) (from milk ), Maltodextrin, Potato starch, Maize starch, Lactose (from milk ), Fructo-oligosaccharides (FOS), Fish oil, Potassium dihydrogen phosphate, Calcium phosphate, Calcium chloride, Choline chloride, Oil from Mortierella Alpina, Magnesium hydrogen phosphate, Potassium chloride, Sodium chloride, Vitamin C, Inositol, Taurine, Ferrous sulphate, L-Carnitine, Zinc sulphate, Uridine 5'-monophosphate sodium salt, Vitamin E, Cytidine 5'-monophosphate, Pantothenic acid, Adenosine 5'-monophosphate, Inosine 5'-monophosphate sodium salt, Nicotinamide, Guanosine 5'-monosulphate sodium salt, Copper sulphate, Riboflavin, Emulsifer ( Soy lecithin), Vitamin A, Thiamin, Vitamin B 6 , Potassium iodide, Folic acid, Antioxidant (Ascorbyl palmitate), Manganese sulphate, Sodium selenite, Vitamin K 1 , Vitamin D 3 , Biotin, Vitamin B 12

Associated Factors: Is there abdominal pain, weight loss, or a change in bowel habits
Results Patients lose an average of 10-15% of body weight over 68 weeks in registration trials for FDA-approved formulations